The Petrochemical Industry in Europe Current Situation and Challenges

November 16, 2016

Strong innovation efforts will generate new growth clusters: Efficient Energy use, health and new materials which could solve upcoming societal mega challenges .95% of all manufactured goods are based on petrochemicals, such as electronics, furniture, appliances, textiles, and many more benefits: sustainable solutions to energy savings and comfort, for example insulation, durable, light-weight and resistant composites, etc.

Spotlight

Dicerna Pharmaceuticals, Inc.

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, known as RNA interference or RNAi, uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in preclinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH.We expect to launch additional GalXC™ programs in HBV, cardiovascular disease targeting PCSK9, and another in an undisclosed genetic ra

OTHER WHITEPAPERS
news image

Implementing a Successful Oil & Gas Sampling Program

whitePaper | July 15, 2021

With aging equipment and facilities, operators face increasing challenges in maintaining equipment reliability, integrity and safety. One of the biggest hidden threats to efficient and safe operation is deteriorating sampling equipment. However, oil and gas companies often operate sampling systems as separate entities within their systems. This leaves operations open to gaps and potential risks in their sampling system.

Read More
news image

LATIN AMERICA PETROCHEMICALS AND CHEMICALS 2019

whitePaper | November 27, 2019

In this challenging environment, it is key for petrochemical and chemical producers to be efficient and to manage closely their production and logistics chains. We live in a world of product abundance as a result of the shale gas revolution, so the market will be taken by those who can be the most competitive. In this respect, the region needs to take advantage of its geological potential, with the pre-salt fields in Brazil and Argentina’s Vaca Muerta developments, as well as Mexico’s injection of funds to Pemex to help the state-oil company recover its past grandeur.

Read More
news image

Technology options for CO2- emission reduction of hydrogen feedstock in ammonia production

whitePaper | February 19, 2022

Ammonia is a focal point for the development of the hydrogen economy. As the main intermediate product used in fertilizer production, ammonia is also the main building block for mineral fertilizers.

Read More
news image

Investor Update October 2022

whitePaper | October 11, 2022

Completed to acquire additional stakes in Lotus Pharmaceutical to be 37% and invest in Adalvo 60%. Profit contribution started in 2Q22

Read More
news image

Why Deck 7

whitePaper | January 1, 2020

With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.

Read More
news image

AI in Chemicals Manager’s Playbook for Getting Value from AIin the Chemicals Sector

whitePaper | February 1, 2023

Technologies like artificial intelligence (AI) and machine learning (ML) are transforming the way industries think about and consume data to drive operational efficiencies and enhance business performance.

Read More

Spotlight

Dicerna Pharmaceuticals, Inc.

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, known as RNA interference or RNAi, uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in preclinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH.We expect to launch additional GalXC™ programs in HBV, cardiovascular disease targeting PCSK9, and another in an undisclosed genetic ra

Events